Celgene Corporation (NASDAQ:CELG) announced detailed results from the phase III SUNBEAM™ trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective …
Michael Pachter bumps up his price target on TWTR, but remains apprehensive on user/advertiser prospects.
Tim Long says the only strength of NOK’s quarterly print stems from a one-time item.
Gilead Sciences, Inc. (NASDAQ:GILD) shares fell nearly 4% in the extended session Thursday after the biotech giant released its third-quarter results, showing weaker sales …
This afternoon, Amazon.com, Inc.
Cantor: CELG pipeline needs commercial juice; Cowen: Sarepta soars on strong Exondys 51 orphan launch.
Eric Schmidt worries CELG investors will further question franchises’ longevity in the 3Q earnings aftermath.
Baird praises TWTR’s improved audience engagement that benefited from product/ad format changes.
Matt Ramsay: Brush off AMD margin confusion; Ben Kallo: Any TSLA pullbacks indicate time to add positions.
Daniel Ives angles for 3Q upside from AMZN tomorrow; Steven Pelayo joins AAPL bulls ahead of FQ4 print.
